Serum and ascitic fluid CA-125 level in patients with ascites. 2007

M Azmi, and M Ghanavati, and M R Keramati, and M Bashashati, and E Hajiani, and A Masjedi, and S J Hashemi

UI MeSH Term Description Entries
D008297 Male Males
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001201 Ascites Accumulation or retention of free fluid within the peritoneal cavity.
D001202 Ascitic Fluid The serous fluid of ASCITES, the accumulation of fluids in the PERITONEAL CAVITY. Peritoneal Effusion,Peritoneal Fluid,Ascitic Fluids,Effusion, Peritoneal,Fluid, Ascitic,Fluid, Peritoneal,Peritoneal Effusions,Peritoneal Fluids
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control
D018394 CA-125 Antigen A carbohydrate antigen that occurs in tumors of the ovary as well as in breast, kidney, and gastrointestinal tract tumors and normal tissue. While it is tumor-associated, it is not tumor-specific and may have a protective function against particles and infectious agents at mucosal surfaces. Antigen CA-125,CA 125 Antigen,Mucin-16,Antigen CA 125,Antigen, CA 125,Antigen, CA-125,Mucin 16

Related Publications

M Azmi, and M Ghanavati, and M R Keramati, and M Bashashati, and E Hajiani, and A Masjedi, and S J Hashemi
October 1999, Gastroenterologia y hepatologia,
M Azmi, and M Ghanavati, and M R Keramati, and M Bashashati, and E Hajiani, and A Masjedi, and S J Hashemi
September 1985, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology,
M Azmi, and M Ghanavati, and M R Keramati, and M Bashashati, and E Hajiani, and A Masjedi, and S J Hashemi
July 1987, Geburtshilfe und Frauenheilkunde,
M Azmi, and M Ghanavati, and M R Keramati, and M Bashashati, and E Hajiani, and A Masjedi, and S J Hashemi
January 1997, Anticancer research,
M Azmi, and M Ghanavati, and M R Keramati, and M Bashashati, and E Hajiani, and A Masjedi, and S J Hashemi
January 1991, Annales chirurgiae et gynaecologiae,
M Azmi, and M Ghanavati, and M R Keramati, and M Bashashati, and E Hajiani, and A Masjedi, and S J Hashemi
December 1984, Rinsho byori. The Japanese journal of clinical pathology,
M Azmi, and M Ghanavati, and M R Keramati, and M Bashashati, and E Hajiani, and A Masjedi, and S J Hashemi
January 1988, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
M Azmi, and M Ghanavati, and M R Keramati, and M Bashashati, and E Hajiani, and A Masjedi, and S J Hashemi
February 2006, The American journal of the medical sciences,
M Azmi, and M Ghanavati, and M R Keramati, and M Bashashati, and E Hajiani, and A Masjedi, and S J Hashemi
October 2011, Diagnostic cytopathology,
M Azmi, and M Ghanavati, and M R Keramati, and M Bashashati, and E Hajiani, and A Masjedi, and S J Hashemi
January 2008, The Netherlands journal of medicine,
Copied contents to your clipboard!